BCL2L1 and Thrombocytopenia: In light of this promising activity of navitoclax in combination with irinotecan for FLC models, we next assessed whether DT2216 might have comparable or improved targeting of BCL-XL but with a lower degree of thrombocytopenia and, therefore, a wider therapeutic window.